免疫检查点抑制剂相关性肺炎的临床诊断与治疗。
Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
机构信息
Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
出版信息
Thorac Cancer. 2020 Jan;11(1):191-197. doi: 10.1111/1759-7714.13240. Epub 2019 Nov 24.
Abstract
The increasing use of immune checkpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immune checkpoint inhibitors, mainly activated T-cells, can attack normal tissues and organs in the body and lead to a variety of adverse effects. In the lung, these attacks can induce checkpoint inhibitor pneumonitis (CIP). CIP is different from known pulmonary interstitial pneumonitis, and has the potential to be fatal if not treated correctly. In this review, we summarize the characteristics of CIP and provide advice on how to manage this disease.
摘要
免疫检查点抑制剂在肿瘤中的应用日益增多，为晚期肿瘤患者带来了新的生存希望。然而，免疫检查点抑制剂激活的免疫系统，主要是激活的 T 细胞，可攻击体内的正常组织和器官，导致多种不良反应。在肺部，这些攻击可诱发免疫检查点抑制剂性肺炎（CIP）。CIP 不同于已知的肺间质肺炎，如不正确治疗，有致命的可能。本综述总结了 CIP 的特征，并就如何管理该病提供了建议。
相似文献
1
Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.免疫检查点抑制剂相关性肺炎的临床诊断与治疗。
Thorac Cancer. 2020 Jan;11(1):191-197. doi: 10.1111/1759-7714.13240. Epub 2019 Nov 24.
2
[Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor].[免疫检查点抑制剂相关肺炎的临床诊断与治疗建议]
Zhongguo Fei Ai Za Zhi. 2019 Oct 20;22(10):621-626. doi: 10.3779/j.issn.1009-3419.2019.10.03.
3
Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy.靶向治疗和免疫检查点抑制剂治疗的眼部毒性的临床诊断和治疗建议。
Thorac Cancer. 2020 Mar;11(3):810-818. doi: 10.1111/1759-7714.13327. Epub 2020 Feb 4.
4
Management of immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关皮肤不良反应的管理。
Thorac Cancer. 2020 Feb;11(2):488-492. doi: 10.1111/1759-7714.13275. Epub 2019 Dec 9.
5
Management of immune checkpoint inhibitor-related rheumatic adverse events.免疫检查点抑制剂相关风湿性不良事件的管理。
Thorac Cancer. 2020 Jan;11(1):198-202. doi: 10.1111/1759-7714.13249. Epub 2019 Nov 24.
6
Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections.免疫检查点抑制剂相关感染的诊断和管理建议。
Thorac Cancer. 2020 Mar;11(3):805-809. doi: 10.1111/1759-7714.13313. Epub 2020 Jan 22.
7
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.免疫检查点抑制剂相关肺炎在非小细胞肺癌中的特征、诊断和管理的最新认识。
Front Immunol. 2021 May 28;12:663986. doi: 10.3389/fimmu.2021.663986. eCollection 2021.
8
Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.免疫检查点抑制剂相关内分泌功能障碍的临床诊断与治疗。
Thorac Cancer. 2020 Apr;11(4):1099-1104. doi: 10.1111/1759-7714.13347. Epub 2020 Feb 11.
9
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.免疫检查点抑制剂相关血液学不良事件的临床诊断和治疗建议。
Thorac Cancer. 2020 Mar;11(3):799-804. doi: 10.1111/1759-7714.13281. Epub 2020 Feb 3.
10
Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system.免疫检查点抑制剂相关消化系统不良反应的临床诊断与治疗。
Thorac Cancer. 2020 Apr;11(4):829-834. doi: 10.1111/1759-7714.13338. Epub 2020 Feb 28.
引用本文的文献
1
Recurrent Checkpoint Inhibitor-Related Pneumonitis Refractory to Corticosteroid Treatment: A Case Report and Literature Review.复发性检查点抑制剂相关性肺炎对皮质类固醇治疗无效：一例报告及文献综述
Clin Pharmacol. 2025 Aug 19;17:235-242. doi: 10.2147/CPAA.S534323. eCollection 2025.
2
One-year mortality risk prediction model for patients with interstitial lung disease and lung cancer.间质性肺疾病合并肺癌患者的一年死亡风险预测模型
Transl Lung Cancer Res. 2025 May 30;14(5):1786-1803. doi: 10.21037/tlcr-2025-235. Epub 2025 May 22.
3
Clinical management of checkpoint inhibitor pneumonitis: Focus, challenges, and future directions.检查点抑制剂肺炎的临床管理：重点、挑战及未来方向
Chin Med J Pulm Crit Care Med. 2025 Mar 8;3(1):29-40. doi: 10.1016/j.pccm.2024.12.001. eCollection 2025 Mar.
4
Long-term outcomes in patients with immune checkpoint inhibitor induced pneumonitis.免疫检查点抑制剂诱发肺炎患者的长期预后
BMJ Open Respir Res. 2023 Apr 6;10(1):e001342. doi: 10.1136/bmjresp-2022-001342.
5
The landscape of immunogenic cell death-related genes predicts the overall survival and immune infiltration status of non-small-cell lung carcinoma.免疫原性细胞死亡相关基因图谱可预测非小细胞肺癌的总生存期和免疫浸润状态。
Heliyon. 2024 Dec 11;11(1):e40869. doi: 10.1016/j.heliyon.2024.e40869. eCollection 2025 Jan 15.
6
Clinical characteristics and biomarkers of severe immune checkpoint inhibitor-related pneumonitis triggered by immunotherapy followed by radiation: a case report.免疫治疗后放疗引发的严重免疫检查点抑制剂相关性肺炎的临床特征及生物标志物：一例报告
Front Immunol. 2024 Nov 22;15:1454114. doi: 10.3389/fimmu.2024.1454114. eCollection 2024.
7
Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors.接受免疫检查点抑制剂治疗患者的不良心血管事件及心脏影像学表现
PLoS One. 2024 Dec 2;19(12):e0314555. doi: 10.1371/journal.pone.0314555. eCollection 2024.
8
Identifying risk factors and biomarkers for severe CIP in lung cancer patients- a retrospective case series study.肺癌患者严重化疗引起的周围神经病变的危险因素及生物标志物识别——一项回顾性病例系列研究
Immunotherapy. 2024;16(18-19):1131-1140. doi: 10.1080/1750743X.2024.2429369. Epub 2024 Nov 26.
9
Cyclosporine successfully treats steroid-resistant checkpoint inhibitor-related pneumonitis: a case report.环孢素成功治疗类固醇耐药的检查点抑制剂相关肺炎：病例报告。
BMC Pulm Med. 2024 Nov 21;24(1):577. doi: 10.1186/s12890-024-03258-5.
10
[Immune-related severe pneumonia: A case report].[免疫相关性重症肺炎：一例病例报告]
Beijing Da Xue Xue Bao Yi Xue Ban. 2024 Oct 18;56(5):932-937. doi: 10.19723/j.issn.1671-167X.2024.05.029.
本文引用的文献
1
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.癌症患者发生免疫相关不良事件后免疫检查点抑制剂再给药的评估。
JAMA Oncol. 2019 Sep 1;5(9):1310-1317. doi: 10.1001/jamaoncol.2019.1022.
2
Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.晚期非小细胞肺癌患者放疗与免疫检查点抑制剂相关性肺炎的关系。
Clin Lung Cancer. 2019 Jul;20(4):e470-e479. doi: 10.1016/j.cllc.2019.02.018. Epub 2019 Mar 28.
3
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.临床试验中 PD-1 和 PD-L1 抑制剂的治疗相关不良反应：系统评价和荟萃分析。
JAMA Oncol. 2019 Jul 1;5(7):1008-1019. doi: 10.1001/jamaoncol.2019.0393.
4
Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.免疫检查点抑制剂治疗实体瘤相关肺炎和间质性肺病的风险：系统评价和荟萃分析。
Front Immunol. 2019 Feb 4;10:108. doi: 10.3389/fimmu.2019.00108. eCollection 2019.
5
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.晚期癌症患者中免疫检查点抑制剂相关肺炎的相对风险和发病率：一项荟萃分析
Front Pharmacol. 2018 Dec 11;9:1430. doi: 10.3389/fphar.2018.01430. eCollection 2018.
6
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.预先存在的肺纤维化是非小细胞肺癌患者抗 PD-1 相关肺炎的一个危险因素：一项回顾性分析。
Lung Cancer. 2018 Nov;125:212-217. doi: 10.1016/j.lungcan.2018.10.001. Epub 2018 Oct 3.
7
Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.非小细胞肺癌患者免疫检查点抑制剂相关肺炎的特征、发生率和危险因素。
Lung Cancer. 2018 Nov;125:150-156. doi: 10.1016/j.lungcan.2018.09.015. Epub 2018 Sep 18.
8
Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.免疫检查点抑制剂治疗非小细胞肺癌患者的肺炎：发生率和危险因素。
J Thorac Oncol. 2018 Dec;13(12):1930-1939. doi: 10.1016/j.jtho.2018.08.2035. Epub 2018 Sep 26.
9
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.非小细胞肺癌患者免疫相关不良事件的发生率、风险因素及对生存的影响。
Clin Lung Cancer. 2018 Nov;19(6):e893-e900. doi: 10.1016/j.cllc.2018.08.008. Epub 2018 Aug 22.
10
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.免疫检查点抑制剂治疗非小细胞肺癌：获益与肺部毒性。
Chest. 2018 Dec;154(6):1416-1423. doi: 10.1016/j.chest.2018.08.1048. Epub 2018 Sep 4.
Zotero 插件